Cambridge, UK - 21st October 2016
Following completion of the first stage of its collaboration with Nuformix, Magnus Life Science has filed its first patent covering novel forms of a lead compound. The Magnus patent will be published in due course.
Nuformix Chief Executive Officer, Dr Dan Gooding, said: “I’m really pleased to see yet another patent filed as a result of our collaborative work. Nuformix continues to find ways to protect, enable and differentiate a wide range of therapeutic molecular entities and we are working to secure further collaborative projects alongside our in-house development programmes.”